StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...

A new study has found that people who spend time on their devices in bed are likely to suffer from sleep loss and insomnia.

Shares of ResMed Inc. RMD slid 3.83% to $205.17 Friday, on what proved to be an all-around dismal trading session for the ...

The home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea ...

A new Resmed-supported study showing sleep apnea patients on CPAP therapy live longer will further fuel a “once-in-a-generation opportunity” to increase awareness, says Carlos Nunez, ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

By examining financial metrics, experts have insights into where the Australian healthcare market is today and where it might ...

ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to ...

Which is the better option for ASX investors, Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) or ResMed Inc. (ASX: RMD) ...

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. Patient monitoring companies within the ...